
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026
Arbutus reports third quarter 2026 net income of $59.1 million and $337.5 million in cash, cash equivalents and marketable securities.
$ABUSHealthcareClinical evidenceExecution and funding risk
ABUS Stock Hub: Arbutus Biopharma News, AB-101 and Capital Return
Arbutus regained U.S. regulatory flexibility for AB-101 after the October hold removal, but a new study remains a development decision. Its completed tender accepted 46 million shares at $5, returning $230 million before expenses. Third-quarter results on November 10 reported $337.5 million of cash and securities at September 30, before the tender payment settled on October 5; a Federal Circuit decision on Moderna’s §1498 appeal, argued on November 5, is pending.
Full research report · PDF
Arbutus Biopharma ($ABUS), research as of October 23, 2026
17 pages covering The archived report separates AB-101 and imdusiran clinical development from intellectual-property recoveries and Genevant economics. It traces the Moderna settlement receipt, conditional litigation paths, the completed 46 million-share tender, June cash flow and the gap before a reported post-tender balance sheet. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next litigation and development checkpoints
No announced date · Federal Circuit decision on Moderna’s §1498 appeal
Expedited oral argument on Moderna’s §1498 appeal was held at the U.S. Court of Appeals for the Federal Circuit on November 5, 2026, and the company says a decision is forthcoming. A ruling favorable to Arbutus and Genevant would trigger an aggregate contingent payment of $1.3 billion from Moderna to the two companies; Arbutus owned approximately 16% of Genevant’s common equity at September 30. Third-quarter 2026 report
Following the October hold removal, Arbutus is still evaluating the next AB-101 development steps, without a trial-start or data date; imdusiran Phase 2b planning is a separate checkpoint, and its timing remains unannounced.
ABUS stock at a glance
Close · November 9, 2026
$3.72
Regular-session close; +1.78% versus $3.655 on November 6, 2026.
Equity value · shares at November 6
~$570.2M
Calculated with the November 9 close and 153,292,826 shares outstanding at November 6 (Form 10-Q cover).
Cash + marketable securities
$337.5M
September 30, 2026; before the $230M tender payment settled October 5. Primary source
Settlement cash received
$178.4M
Arbutus share received July 8, 2026.
Tender purchase price
$230M
46M shares accepted at $5; excludes fees, October 1 final results.
Shares outstanding · November 6
153.293M
Form 10-Q cover, after cancellation of the 46M tendered shares on October 5. Primary source
Nine-month operating cash flow
+$225.7M
Nine months to September 30, including the settlement receipt; not recurring.
Q3 net income
$59.1M
Driven by a $67.3M Genevant dividend; third-quarter revenue was $0.3M.
Where Arbutus Biopharma stands now
Arbutus Biopharma Corporation is a Canadian-incorporated, Nasdaq-listed clinical-stage company whose current therapeutic focus is chronic hepatitis B. Its two named programs are imdusiran, also called AB-729, and the oral PD-L1 inhibitor AB-101. The company also participates in the economics of delivery-technology intellectual property licensed to Genevant. That makes ABUS different from a conventional single-trial biotech: clinical development, contractual income and litigation can affect the same equity through different channels. At June 30, 2026, Arbutus reported $19.171 million of cash and equivalents plus $73.454 million of marketable securities, for combined liquidity of $92.625 million. The July $178.4 million settlement receipt occurred after that balance-sheet date. The later tender committed $230 million before fees. These observations describe a sequence, not a current balance that can be obtained by presenting the June figure unchanged.
On November 10, 2026 Arbutus reported third-quarter results. Cash, cash equivalents and marketable securities were $337.5 million at September 30, after the $178.4 million settlement share received in July and a $67.3 million cash dividend from Genevant in September; the balance sheet also carried a $230 million obligation to repurchase shares, settled on October 5 with the cancellation of 46 million shares. Deducting that payment alone leaves about $107.5 million (Merlintrader calculation, before tender expenses and later operating flows). Third-quarter revenue was $0.3 million, R&D expenses $2.6 million, G&A $8.0 million (including one-time cash bonuses to executives tied to the Moderna settlement) and net income $59.1 million, driven by the dividend. Shares outstanding were 153,292,826 at November 6, and the company states that it has sufficient cash to fund operations for at least the next 12 months. On the same day Arbutus and Genevant announced two new lawsuits in Japan against Pfizer Japan and the addition of a newly issued patent to the Canadian case against Pfizer, BioNTech and affiliates; the expedited oral argument on Moderna’s §1498 appeal was held on November 5, with a decision forthcoming. Third-quarter 2026 results and corporate update Third-quarter 2026 Form 10-Q
Regulatory flexibility is not a funded trial. AB-101 next steps, imdusiran development, litigation economics and the post-tender funding base remain separate uncertainties. Settlement income is not recurring revenue; the dated 13G percentage uses its original reference population.
The constructive case
Regulatory flexibility for AB-101, an imdusiran clinical foundation and monetized intellectual property support several possible development paths. A clearly funded next trial would make those paths easier to evaluate, and a ruling favorable to Arbutus and Genevant in Moderna’s §1498 appeal would trigger the $1.3 billion aggregate contingent payment to the two companies.
The cautious case
Early clinical signals still need confirmation. Capital returned through the tender is no longer available to fund the business, and future litigation proceeds remain uncertain. A smaller share count cannot replace clinical execution or turn a conditional recovery into cash. If the appellate ruling is not favorable, the contingent payment is not due; third-quarter G&A rose to $8.0 million, partly because of one-time executive bonuses.
Latest Arbutus Biopharma news
Nov 10, 2026
Arbutus reports third quarter 2026 financial results and provides corporate update
Arbutus reported third quarter 2026 net income of $59.1 million, or $0.30 per basic and diluted common share, and cash, cash equivalents and marketable securities of $337.5 million as of September 30, 2026. The company returned $230 million to shareholders through a tender offer in early October 2026. It filed new LNP patent lawsuits in Japan against Pfizer Japan Inc. and amended a Canadian lawsuit against Pfizer and BioNTech. The FDA lifted the clinical hold on the IND application for AB-101 in October 2026.
Oct 27, 2026
BlackRock files a dated ownership amendment
The Schedule 13G/A reports 14,331,732 beneficially owned shares,7.2% of the class, at September 30. It describes disaggregated reporting business units and ordinary-course holdings without a control purpose. Its reference date precedes the final tender results; the percentage is not recomputed using the later expected share count.
Oct 22, 2026
AB-101 U.S. hold removed
Arbutus may undertake additional U.S. development. The company is evaluating next steps; the release gives no new trial-start or results date.
Oct 1, 2026
final tender results
46 million shares accepted at $5.00 for $230 million before expenses. Expected shares after completion: approximately 153.276 million.
Aug 24, 2026
Tender offer commenced
The company launched the capital-return process under the tender terms. The October 1 final results, described separately, supersede the preliminary offer size and completion assumptions.
Aug 12, 2026
results and clinical alignment
June liquidity was $92.625M and Q2 net loss $5.143M. Arbutus reported FDA design and safety alignment for a proposed imdusiran Phase 2 b study.
ABUS stock catalysts: development and reporting dates
- November 10, 2026 — Third-quarter 2026 results and Form 10-Q: $337.5 million of cash and securities at September 30, before the $230 million tender payment. Completed · company report
- No announced date — Federal Circuit decision on Moderna’s §1498 appeal, argued on November 5, 2026; a favorable ruling triggers a $1.3 billion aggregate contingent payment to Arbutus and Genevant. Pending court decision
- No announced date — AB-101 next development and funding decision. Company evaluation
- No announced study start — Proposed imdusiran Phase 2 b program following FDA alignment. Development planning
Ownership amendment · AB-101 hold removal · Third-quarter 2026 report
AB-101 and imdusiran: different development steps
On October 22, 2026, Arbutus announced that the FDA removed the clinical hold on the AB-101 IND and that additional U.S. clinical development may proceed. The program is an oral PD-L1 inhibitor intended for chronic hepatitis B. The company’s immediate statement was that it is evaluating next steps. The important change is permission to develop, rather than a new approval to market the drug or a commitment to a particular next trial.
The published AB-729-001 Phase 1 a/b study provides a useful independent documentary basis for the early clinical development of imdusiran. The original abstract reports 83 participants who received study treatment or placebo across healthy-volunteer and chronic-HBV parts. Its patient portions were open-label rather than a randomized comparison designed to establish a functional-cure advantage. The main endpoint was safety. These design features define the strength and limits of what the study can support.
ABUS cash after settlement and tender
At June 30, 2026, Arbutus reported $19.171 million of cash and equivalents plus $73.454 million of marketable securities, for combined liquidity of $92.625 million. The July $178.4 million settlement receipt occurred after that balance-sheet date. The later tender committed $230 million before fees. These observations describe a sequence, not a current balance that can be obtained by presenting the June figure unchanged. Operating activities used $14.128 million in the first half, compared with $8.110 million in the first quarter. The calculated second-quarter amount is $6.018 million; the calculated half-year monthly average is about $2.355 million. These are historical operating-cash measures, not a forecast for a larger clinical program. They exclude the later tender and are not a substitute for the company’s next cash-flow statement.
The third-quarter Form 10-Q, filed November 10, 2026, reports $337.5 million of cash, cash equivalents and marketable securities and no debt at September 30. Nine-month operating cash flow was a positive $225.7 million because of the settlement receipt, and stock-option exercises brought in $19.3 million. The $230 million repurchase was recorded as a current liability at September 30 and paid with available cash when the tender settled on October 5; deducting it gives about $107.5 million (Merlintrader calculation, before tender expenses). At September 30 the company also had 6.4 million stock options and unvested restricted stock units outstanding. Third-quarter 2026 Form 10-Q Third-quarter 2026 results
Merlintrader Health Score · $ABUS
3.35out of 5
Assessed November 10, 2026, after the third-quarter 2026 report: financial resources raised from 3.0 to 4.0 once the post-settlement balance was reported, catalysts from 2.5 to 3.0 for the pending appellate decision; other scores unchanged from the October 22 assessment. Weighted calculation: 4.0×30% + 3.0×30% + 3.5×20% + 3.0×10% + 2.5×10% = 3.35. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- The $1.3 billion aggregate contingent payment depends entirely on a favorable appellate ruling and would be shared between Arbutus and Genevant.
- AB-101 next steps, imdusiran development, litigation economics and the post-tender funding base remain separate uncertainties. Settlement income is not recurring revenue; the dated 13G percentage uses its original reference population.
- Early clinical signals still need confirmation. Capital returned through the tender is no longer available to fund the business, and future litigation proceeds remain uncertain. A smaller share count cannot replace clinical execution or turn a conditional recovery into cash.
ABUS Stock FAQ: Arbutus Biopharma Questions Answered
What is the next catalyst for ABUS stock?
As of November 10, 2026, the nearest identified event was the Federal Circuit decision on Moderna’s §1498 appeal, argued on November 5, with no announced decision date; a favorable ruling would trigger a $1.3 billion aggregate contingent payment to Arbutus and Genevant. Arbutus was also evaluating AB-101’s next development steps without an announced new trial-start or readout date. Its October 22 update followed removal of the US clinical hold. Separately, the August update described FDA alignment on a proposed imdusiran Phase 2b design, rather than an enrolled study with scheduled results. AB-101 hold removal and evaluation of next steps. Proposed imdusiran trial design. Appeal status in the third-quarter report. Current company announcements.
Are Arbutus Biopharma’s AB-101 and imdusiran FDA approved?
No. Arbutus’s October 22, 2026 announcement reports removal of the clinical hold on AB-101’s IND, permitting further US development rather than commercial sales. Imdusiran remained an investigational chronic-hepatitis-B program in the August update, with Fast Track designation and alignment on a proposed Phase 2b protocol. These regulatory steps are not evidence of marketing approval. AB-101 investigational status. Imdusiran development and regulatory milestones.
How much cash does Arbutus have after the settlement and tender?
Arbutus reported $337.5 million of cash, equivalents and marketable securities at September 30, 2026, after the $178.4 million settlement share received in July and a $67.3 million Genevant dividend in September. The $230 million tender payment, recorded as a liability at that date, was paid when the tender settled on October 5; deducting it gives about $107.5 million (Merlintrader calculation, before tender expenses and later operating flows). The company states it has sufficient cash for at least the next 12 months. September liquidity and tender settlement. Earlier reference: June 30 liquidity was $92.625 million. June liquidity, operating cash use and subsequent settlement receipt. Tender consideration and expenses.
How did Arbutus’s tender change the ABUS share count?
Arbutus’s October 1, 2026 final tender results accepted 46 million shares for cancellation at $5 each, totaling $230 million before expenses. The company expected 153,275,907 shares outstanding immediately after completion; the third-quarter Form 10-Q reports 153,292,826 shares outstanding at November 6, 2026. This was a repurchase rather than a dividend to continuing holders; stock options and employee equity awards can still create future share claims. Final tender results and expected post-tender common shares. Employee equity compensation.
When will Arbutus Biopharma report its next earnings?
Arbutus reported third-quarter 2026 results on November 10, 2026, for the quarter ended September 30; as of that date it had not announced its next earnings date. Company announcements. November 10 quarterly results.
What does Arbutus Biopharma do?
Arbutus’s October 22, 2026 update describes a clinical-stage biotechnology company developing treatments for chronic hepatitis B. Its programs include RNAi candidate imdusiran, also called AB-729, and oral PD-L1 inhibitor AB-101. It also supports licensee Genevant’s protection and enforcement of lipid-nanoparticle delivery patents, creating separate intellectual-property economics alongside drug development. Company programs and delivery-technology licensing.
Does Arbutus’s reported 47% mean an imdusiran functional-cure rate?
No. Arbutus’s August 12, 2026 filing describes 47%, or 49 of 105 Phase 2a patients, as a combined group who achieved functional cure or remained off nucleos(t)ide analogue therapy. Remaining off that therapy is a different outcome. The filing separately discusses functional-cure observations, follow-up periods and patients who later seroreverted. Phase 2a outcomes and long-term follow-up definitions.
Did Arbutus receive the entire Moderna settlement payment?
No. Arbutus received $178.4 million on July 8, 2026 as its share of the initial payment, including litigation-cost reimbursement. Its August filing describes $950 million paid collectively to Arbutus and Genevant, plus a separate $1.3 billion contingent payment tied to an appellate ruling. Those aggregate amounts are not all cash received by Arbutus. In September Arbutus also received a $67.3 million cash dividend from Genevant, of which it owned approximately 16% of the common equity, and on November 5 the Federal Circuit heard expedited oral argument on the appeal; a decision is forthcoming. Moderna settlement allocation, actual receipt and contingent component.
Primary sources
- November 10, 2026 · third-quarter results, Japan lawsuits and appeal status
- November 10, 2026 · Form 10-Q for the quarter ended September 30
- October 27, 2026 · BlackRock files a dated ownership amendment
- October 22, 2026 · AB-101 U.S. hold removed
- October 1, 2026 · final tender results
- August 24, 2026 · Tender offer commenced
- August 12, 2026 · results and clinical alignment
- July 16, 2026 · settlement receipt and expanded litigation
This blog content is provided for informational and educational purposes only. It is not investment advice.
Disclaimer. Merlintrader publishes educational and informational analysis. This is not investment advice, a recommendation or an offer to buy or sell any security. Clinical observations and company development targets are not guarantees of approval or commercial success.
Early-stage biotech companies face clinical, regulatory, financing, competition and execution risks. Litigation outcomes and contingent payments are uncertain. Investors may lose part or all of their capital. Figures retain their reference dates and can change. Readers should perform their own research and consult a licensed financial adviser where appropriate.
Artificial intelligence supports research and organization under editorial supervision. The cover is an illustrative generated image, not a photograph of an Arbutus facility or product. Merlintrader may hold positions in mentioned securities. Affiliate links, including Finviz, may generate a commission at no additional cost. See the disclaimer and terms and privacy information.



